CAJ | 학술논문

继发性甲状旁腺功能亢进(SHPT)是慢性肾脏疾病最常见的并发症之一。度骨化醇是一种选择性维生素D受体激动剂，在肝脏中代谢，对骨骼和肠道的影响较小。度骨化醇主要作用于甲状旁腺，能够有效地抑制全段甲状旁腺激素(iPTH)的分泌，较小程度增加血钙和血磷浓度。度骨化醇被FDA批准用于降低进行性慢性肾透析的SHPT患者的iPTH水平。与骨化三醇相比，高钙血症和高磷血症的发生率低，更加安全有效，是骨化三醇和阿法骨化醇的升级换代产品。
계발성갑상방선공능항진(SHPT)시만성신장질병최상견적병발증지일。도골화순시일충선택성유생소D수체격동제，재간장중대사，대골격화장도적영향교소。도골화순주요작용우갑상방선，능구유효지억제전단갑상방선격소(iPTH)적분비，교소정도증가혈개화혈린농도。도골화순피FDA비준용우강저진행성만성신투석적SHPT환자적iPTH수평。여골화삼순상비，고개혈증화고린혈증적발생솔저，경가안전유효，시골화삼순화아법골화순적승급환대산품。
Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. Doxercalcifer-ol, which is a selective vitamin D receptor activator is activated in the liver, and has little effect on bone and intestine. Doxercalciferol acts on parathyroid gland, suppress intact parathyroid hormone (iPTH) effectively with minimal increas-es in serum calcium and phosphorus (P) levels. Doxercalciferol has recently been approved by FDA for the reduction of iPTH in haemodialysis patients suffering from SHPT. It demonstrated a lower propensity to cause hypercalcemia and hypercalciuria than calcitriol, and is an alternative to calcitriol.